# US 2018/0118724 A1 · Receptor-Type Kinase Modulators and Methods of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0118724 A1
- Document ID: US20180118724A1
- Status: Published application
- Kind: A1
- Application number: 15/692,445
- Filed: 2018-01-15
- Published: 2018-05-03
- Earliest claimed: 2002-07-15
- Assignees: Symphony Evolution, Inc.
- Applicants: Symphony Evolution, Inc.
- Inventors: Kenneth D. Rice; Neel K. Anand; Joerg Bussenius; Simona Costanzo; Abigail R. Kennedy; Csaba J. Peto; Tsze H. Tsang; Charles M. Blazey
- Web page: https://patentgrep.com/patent/US20180118724A1

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/94: Nitrogen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 451/06: Oxygen atoms
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 493/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

## Claims

### Claim 1

A solid dosage formulation comprising a therapeutically effective amount of a compound of Formula I,
or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof, together with one or more materials selected from excipients (or carriers), fillers, extenders, binders, humectants, disintegrating agents, solution retarders, absorption accelerators, wetting agents, adsorbents, lubricants, and buffering agents, wherein the solid dosage form is a pill, tablet, or capsule, and wherein,
R1 is methyl;
R2 is selected from halogen, trihalomethyl, —CN, —NH2, —NO2, —OR3, —N(R3)R4, —S(O)O2R4, —SO2N(R3)R4, —CO2R3, —C(═O)N(R3)R4, —N(R3)SO2R4, —N(R3)C(═O)R3, —N(R3)CO2R4, —C(═O)R3, lower alkyl, lower alkenyl, and lower alkynyl;
R3 is —H or R4;
R4 is selected from lower alkyl; lower alkyl substituted with one, two, or three halogen; aryl; aryl substituted with one, two, or three halogen; and unsubstituted lower arylalkyl; or
R3 and R4, when taken together with a common nitrogen to which they are attached, form morpholinyl, pyrrolidinyl, piperidinyl. or piperazinyl optionally substituted by one, two, or three alkyl;
q is 0, 1, 2, 3, 4, or 5;
Z is —NR—;
R5 is —H;
M1-M2-M3-M4-together are according to formula II:
wherein X1, X2, and optionally X3, represent the atoms of a saturated bridged ring system, said saturated bridged ring system containing up to three annular heteroatoms represented by any of X1, X2, and X3; wherein,
each X1 is independently selected from —C(R6)R7—, —O—, —S(O)0-2—, and —NR8—;
each X2 is independently a bridgehead methine optionally substituted with R6, or a bridgehead nitrogen;
each X3 is independently selected from —C(R6)R7, —O—, —S(O)0-2—, and —NR8—;
provided, for X1, X2, and X3, there are no nitrogen-nitrogen annular bonds nor geminal di-nitrogen substitutions;
E is absent;
Y is —CH2— provided that Y is not directly attached to any heteroatom represented by X1, X2 or X3;
m and p are each independently 1, 2, 3, or 4;
n is 0, 1, or 2, when n is zero, then there is a direct single bond between the two bridgehead X2's;
R6 and R7 are each independently selected from —H, halogen, trihalomethyl, —CN, —NH2, —NO2, —OR3, —N(R3)R4, —S(O)o-2R4, —SO2N(R3)R4, —CO2R3, —C(O)N(R3)R4, —N(R3)SO2R4, —N(R3)C(O)R3, —NCO2R3, —C(O)R3, lower alkyl, aryl, and unsubstituted lower arylalkyl; or
R6 and R7, when taken together are oxo; or
R6 and R7, when taken together with a common carbon to which they are attached, form a three- to seven-membered spirocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P and wherein the spirocyclic ring is optionally substituted with one or two alkyl; and
R8 is selected from R3, —SO2N(R3)R4, —CO2R3, —C(O)N(R3)R4, —SO2R4, and —C(O)R3;
with the proviso that when Y is a C1-3 alkylene linker, E is absent, Z is —NH— or —N(CH3)—, R1 is a C1-3 alkyl, R2 is —H or halogen, n=O, and the atoms X1 of one bridge of the saturated bridged ring system, when combined with both bridgehead atoms, X2, of the saturated bridged ring system, represent:
either a pyrrolidine ring or a piperidine ring, and any atom, X1 or X2, of either of said pyrrolidine ring or said piperidine ring is attached to Y; then the other bridge of said saturated bridged ring system cannot be any one of —OC(O)CH2—, —CH2OC(O)—, —OC(O)CH2CH2—, —CH2OC(O)CH2—, —CH2CH2OC(O)—, —OC(O)CH2NH—, —OC(O)CH2N(C14alkyl)-, and —OC(O)CH2O—; and
either a piperazine ring or a 4-(C1-4 alkyl)-piperazine ring, and any atom, X1 or X2, of either of said piperazine ring or said 4-(C1-4 alkyl)-piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 2- and the 3-position of either of said piperazine ring or said 4-(C1-4 alkyl)-piperazine ring, cannot be one of —CH2OC(O)CH2—, —CH2CH2OC(O)—, and either of the two aforementioned bridges substituted by one or two C1-alkyl groups; and
a piperazine ring, and any atom, X1 or X2, of said piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 3- and the 4-position of said piperazine ring, cannot be —C(O)OCH2CH2—, —CH2OC(O)CH2—, —C(O)OCH2CH2— substituted with one or two C1-2 alkyl groups, or —CH2OC(O)CH2— substituted with one or two C1-2 alkyl groups (but only when the four above mentioned bridges are attached to the 3-position of said piperazine ring via their left-hand end as depicted above); and
a 2-oxomorpholine ring, said 2-oxomorpholine ring attached to Y via its 4-position; then the other bridge of said saturated bridged ring system, only when attached via the 5- and the 6-position of said 2-oxomorpholine ring, cannot be one of —(CH2)g—, —CH2WCH2—, —CH2WCH2CH2—, and —CH2CH2WCH2, wherein W is —O—, —S(O)0-2—, —NH—, or —N(C1-4 alkyl)- and wherein g is 2, 3, or 4.

### Claim 2 (depends on 1)

The solid dosage form according to claim 1, wherein R2 is selected from halogen, trihalomethyl, —CN, —NO2, —OR3, and lower alkyl; or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The solid dosage form according to claim 2, wherein the saturated bridged ring system has a geometry selected from the group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], [3.1.0], [3.3.3], [3.3.2], [3.3.1], [3.2.2], [3.2.1], [2.2.2], and [2.2.1]; or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

The solid dosage form according to claim 3, wherein q is 1, 2, or 3; or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The solid dosage form according to claim 4, wherein the saturated bridged ring system has a geometry selected from the group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], and [3.1.0]; or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The solid dosage form according to claim 5, wherein said saturated bridged ring system contains one or two annular nitrogens, said one or two annular nitrogens are selected from —NR8—, when X1, and a bridgehead nitrogen, when X2; or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The solid dosage form according to claim 6, wherein said saturated bridged ring system is according to either formula V or formula VI,
wherein R8 is selected from —H, lower alkyl, —COR3, —C(O)N(R3)R4, —SO2R4, and —C(O)R3; or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The solid dosage form according to claim 7, wherein
of I is selected from
wherein R2a, R2b, and R2c are each independently selected from F, Cl, and Br; or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The solid dosage form according to claim 8, wherein R2a is F, R2b is Cl, and R2c is either Cl or Br; or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The solid dosage form according to claim 9, wherein R8 is methyl or ethyl; or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The solid dosage form of claim 1 wherein the compound is N-(3,4-dichloro-2-fluorophenyl)-7-({[(3 aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A method of inhibiting a receptor tyrosine kinase in a cell in a human, wherein the receptor tyrosine kinase is selected from the group consisting of kinase insert domain receipt, epidermal growth factor receptor, and ErbB2, the method comprising administering to the human a solid dosage formulation according to claim 1.

### Claim 13 (depends on 3)

A method of inhibiting a receptor tyrosine kinase in a cell in a human, wherein the receptor tyrosine kinase is selected from the group consisting of kinase insert domain receipt, epidermal growth factor receptor, and ErbB2, the method comprising administering to the human a solid dosage formulation according to claim 3.

### Claim 14 (depends on 7)

A method of inhibiting a receptor tyrosine kinase in a cell in a human, wherein the receptor tyrosine kinase is selected from the group consisting of kinase insert domain receipt, epidermal growth factor receptor, and ErbB2, the method comprising administering to the human a solid dosage formulation according to claim 7.

### Claim 15 (depends on 11)

A method of inhibiting a receptor tyrosine kinase in a cell in a human, wherein the receptor tyrosine kinase is selected from the group consisting of kinase insert domain receipt, epidermal growth factor receptor, and ErbB2, the method comprising administering to the human a solid dosage formulation according to claim 11.

### Claim 16 (depends on 12)

The method of claim 12, wherein the receptor tyrosine kinase is kinase insert domain receptor.

### Claim 17 (depends on 12)

The method of claim 12, wherein the receptor tyrosine kinase is epidermal growth factor receptor.

### Claim 18 (depends on 12)

The method of claim 12, wherein the receptor tyrosine kinase is ErbB2.

### Claim 19 (depends on 15)

The method of claim 15, wherein the receptor tyrosine kinase is kinase insert domain receptor.

### Claim 20 (depends on 15)

The method of claim 15, wherein the receptor tyrosine kinase is epidermal growth factor receptor.

### Claim 21 (depends on 15)

The method of claim 15, wherein the receptor tyrosine kinase is ErbB2.
